When you stop taking Wegovy, most people regain a significant portion of the weight they lost — often within months. The STEP 4 trial published in JAMA (2021) found that participants who discontinued semaglutide regained about two-thirds of their lost weight within one year. Appetite typically returns, and the metabolic benefits of the drug begin to reverse.
Why Does Weight Come Back After Stopping Wegovy?
Wegovy works by mimicking GLP-1, a hormone your gut naturally releases after eating. Semaglutide binds to GLP-1 receptors in the brain's appetite-regulating centers, slowing gastric emptying and reducing hunger signals. According to the FDA prescribing information, these effects are pharmacological — meaning they depend on the drug being present in your system.
Once you stop injecting, semaglutide clears from your body over roughly five weeks (its half-life is approximately seven days). As levels drop, the appetite suppression fades. For most people, obesity is a chronic condition driven by biology, not willpower. The underlying hormonal environment that made weight loss difficult before Wegovy reasserts itself after stopping.
What Does the Timeline Look Like?
Research from the STEP 4 trial gives the clearest picture of what happens week by week after discontinuation. Participants had completed 20 weeks on semaglutide before stopping.
| Time After Stopping | What Typically Happens |
|---|---|
| Weeks 1–2 | Semaglutide still partly active; minimal changes noticed |
| Weeks 3–5 | Drug largely cleared; appetite begins to increase noticeably |
| Months 2–3 | Hunger returns toward baseline; early weight regain begins |
| Months 3–6 | Accelerated weight regain; blood sugar and blood pressure may rise |
| Month 12 | STEP 4 participants regained ~14 of the ~17 lbs average lost (about two-thirds of total loss) |
| Beyond 12 months | Some individuals continue to regain toward pre-treatment weight |
Most important takeaway: The STEP 4 trial (Rubino et al., JAMA 2021) showed participants who stopped semaglutide regained approximately two-thirds of their lost weight within one year, while those who continued lost an additional 7.9% of body weight. Stopping Wegovy without a follow-on plan makes sustained weight loss very difficult for most people.
Which Health Markers Are Affected?
Weight is not the only thing that changes. The STEP 4 trial tracked several cardiometabolic markers and found that after discontinuation:
- Blood pressure rose toward pre-treatment levels
- Blood sugar (HbA1c) and fasting glucose increased
- Waist circumference expanded as abdominal fat returned
- Cholesterol and triglyceride improvements partially reversed
This pattern is consistent with what the NIH NIDDK notes about obesity medications broadly: their benefits are sustained only as long as the medication is taken. If you stopped Wegovy because of a side effect or cost concern, discuss alternatives with your prescriber rather than stopping without a plan.
Are There Any Lasting Benefits After Stopping?
Some people do retain partial benefits, especially if they used the time on Wegovy to build sustainable habits — consistent physical activity, improved sleep, and dietary changes. However, the evidence does not support the idea that Wegovy permanently resets metabolism or appetite biology. Any behavioral habits you build while on the medication are yours to keep, but the hormonal suppression of hunger does not persist after the drug clears.
A small subset of individuals in clinical trials maintained more weight loss than the average after stopping, which researchers believe reflects stronger lifestyle changes made during treatment. If you are planning to stop, working with a registered dietitian or behavioral health specialist before discontinuing may improve your odds of holding onto some of the loss.
When Might a Doctor Recommend Stopping Wegovy?
There are legitimate medical reasons to discontinue, including:
- Pregnancy or planned pregnancy — the FDA prescribing information states Wegovy should be discontinued at least two months before a planned pregnancy due to its long half-life
- Serious adverse reactions such as pancreatitis, severe gastrointestinal events, or hypersensitivity
- Medullary thyroid carcinoma risk — Wegovy carries a boxed warning; patients with a personal or family history of MTC or MEN2 should not use it
- Inadequate response — if less than 5% body weight is lost after 16 weeks at the maintenance dose, the FDA label recommends reassessing treatment
Frequently Asked Questions
Stopping Wegovy is a significant medical decision with predictable biological consequences for most people. If you are considering discontinuing — whether due to cost, side effects, or reaching a goal weight — your prescriber is the right person to help you weigh the risks, explore alternatives, and build a plan that protects your health after stopping.
- FDA Wegovy (semaglutide) Prescribing Information, 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215256s000lbl.pdf
- Wilding JPH, et al. 'Once-Weekly Semaglutide in Adults with Overweight or Obesity.' NEJM. 2021;384:989-1002. https://www.nejm.org/doi/10.1056/NEJMoa2032183
- Rubino DM, et al. 'Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.' JAMA. 2021;325(14):1414-1425. https://jamanetwork.com/journals/jama/fullarticle/2777886
- NIH National Institute of Diabetes and Digestive and Kidney Diseases. 'Prescription Medications to Treat Overweight & Obesity.' https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity